-
Product Insights
Net Present Value Model: Lepu Biopharma Co Ltd’s MRG-002
Empower your strategies with our Net Present Value Model: Lepu Biopharma Co Ltd's MRG-002 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Lepu Medical Technology (Beijing) Co Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Lepu Medical Technology (Beijing) Co Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The...
-
Sector Analysis
Prosthetic Heart Valves Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Prosthetic Heart Valves Market Report Overview The prosthetic heart valves market size was valued at $2.15 billion in 2023. The prosthetic heart valves market will grow at a CAGR of more than 3% from 2023 to 2033. The growing aging population across the globe and the associated valvular degeneration is primarily driving the prosthetic heart valve market growth. Prosthetic Heart Valves Market Outlook 2023-2033 ($ Billion) Buy the Full Report for More Insights on the Prosthetic Heart Valves Market Forecast,...
-
Product Insights
NewNon Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) – Drugs In Development, 2024
Empower your strategies with our Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) – Drugs In Development, 2024 report and make more profitable business decisions. Non-Muscle-Invasive Bladder Cancer (NMIBC), also referred to as superficial bladder cancer, is a type of bladder cancer that is confined to the innermost lining of the bladder. Unlike muscle-invasive bladder cancer, which penetrates the muscle layer of the bladder wall, NMIBC stays within the lining and does not invade deeper layers or surrounding tissues. NMIBC...
-
Product Insights
NewGastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2024
Empower your strategies with our Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2024 report and make more profitable business decisions. Gastroesophageal (GE) junction carcinomas are malignancies occurring at the point where the esophagus meets the stomach. Typically classified as adenocarcinomas or squamous cell carcinomas, adenocarcinomas are more prevalent. Risk factors include chronic gastroesophageal reflux disease (GERD), obesity, and smoking. Symptoms often manifest in advanced stages, including difficulty swallowing, weight loss, and abdominal pain. Diagnosis involves endoscopic procedures and imaging studies....
-
Sector Analysis
PTCA Balloon Catheters Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
PTCA Balloon Catheters Market Report Overview The PTCA Balloon Catheters market size was valued at $2.20 billion in 2023. The market is expected to grow at a CAGR of more than 2% during 2023-2033. Percutaneous Transluminal Coronary Angioplasty (PTCA) is a minimally invasive procedure to open blocked coronary arteries. A PTCA Balloon Catheter is inserted into blood vessels through the groin or the arm and threaded to the area of blockage. The balloon is inflated to compress the plaque deposited...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-002 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LP-002 in Solid Tumor Drug Details: LP-002 is under development for the treatment of relapsed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tusamitamab Ravtansine in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tusamitamab Ravtansine in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Drug Details: Tusamitamab ravtansine is under development...
-
Product Insights
Ablation Equipment Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Ablation Equipment Pipeline Market Report Overview An Ablation Equipment is a device used to surgically remove a body tissue. The Ablation Equipment pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Territories ·       The US ·       Europe...
-
Product Insights
NewNet Present Value Model: Atai Life Sciences NV’s Ibogaine
Empower your strategies with our Net Present Value Model: Atai Life Sciences NV's Ibogaine report and make more profitable business decisions.Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Atai Life Sciences...